Janssen Submits Supplemental New Drug Application to FDA Seeking New Indications for XARELTO ® (rivaroxaban) for Patients with Chronic Coronary and/or Peripheral Artery Disease (CAD/PAD)
Source: Johnson and Johnson - Category: Pharmaceuticals Source Type: news